A Retrospective Analysis of Treatment of Covid-19 with Favipiravir
By:
References
- 1. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020;83(6):534-6.10.1097/JCMA.0000000000000318717626632243270
- 2. World Health Organization. Weekly epidemiological update on COVID-19 - 13 July 2021 [cited July 15, 2021]. In: World Health Organization [Internet]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021
- 3. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am. J. Emerg. Med. 2020;38(7):1488-93.10.1016/j.ajem.2020.04.035
- 4. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 2013;100(2):446-54.10.1016/j.antiviral.2013.09.015
- 5. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 2020;7(1):11.10.1186/s40779-020-00240-0
- 6. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10), 1192-8.10.1016/j.eng.2020.03.007
- 7. Çalık Başaran N, Uyaroğlu OA, Telli Dizman G, Özışık L, Şahin TK, Taş Z, et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turk. J. Med. Sci. 2021;51(2):411-20.10.3906/sag-2006-173
- 8. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.03.17.20037432
- 9. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. Eur. J. Pharm. Sci. 2021;157.10.1016/j.ejps.2020.105631758571933115675
- 10. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN., еt al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;ciaa1176.10.1093/cid/ciaa1176745438832770240
- 11. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. (2020). Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virology Journal. 2020;17(1):141.10.1186/s12985-020-01412-z
- 12. [Clinical protocol for the diagnosis and treatment of coronavirus infection COVID-19]. Protocol No. 107, Approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan dated July 15, 2020. Available from: www.gov.kz Russian.
DOI: https://doi.org/10.2478/jbcr-2022-0010 | Journal eISSN: 1313-9053
Language: English
Page range: 74 - 78
Submitted on: Jul 22, 2021
Accepted on: May 11, 2022
Published on: Jul 13, 2022
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2022 Sholpan A. Kulzhanova, Maiya E. Konkayeva, Zauresh K. Smagulova, Nazira N. Beisenbieva, Gulnara T. Tuleshova, Aigul M. Utegenova, Gulsimzhan O. Turebaeva, Gaukhar A. Nurakhmetova, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.